IL6R and neutropenia: It is known that both anti-TNFα and anti-IL6R therapies decrease the neutrophil numbers, with the anti-IL6R therapy (TCZ) leading more frequently to neutropenia than the anti-TNFα (e.g., ETA or ADA) therapy (Espinoza et al., 2017[15]; Gaber et al., 2016[18]; Wright et al., 2014[45]).